Akari Therapeutics Announces Interim CEO Employment Contract Demonstrating Alignment with Shareholders
June 05, 2024 08:00 ET
|
Akari Therapeutics Plc
Interim CEO employment contract consists solely of equity compensationSamir R. Patel, M.D., increases ownership to 14.2% with $1.25m investment in recent private placement BOSTON and LONDON, June...
Akari Therapeutics Secures $7.6 Million in Upsized Financing Round
June 04, 2024 08:00 ET
|
Akari Therapeutics Plc
BOSTON and LONDON, June 04, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics Plc (Nasdaq: AKTX), an innovative biotechnology company advancing therapies for autoimmune and inflammatory diseases, today...
Akari Therapeutics Reports First Quarter 2024 Financial Results and Recent Highlights
May 16, 2024 08:00 ET
|
Akari Therapeutics Plc
Entered into a Definitive Merger Agreement with Peak Bio; Expected to Close in the Third Quarter of 2024 Samir R. Patel, M.D. Appointed Interim CEO Plan for Prioritization of Peak Bio’s ADC Cancer...
Samir R. Patel, M.D. Appointed Interim CEO for Akari Therapeutics
May 01, 2024 08:01 ET
|
Akari Therapeutics Plc
BOSTON and LONDON, May 01, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today...
Akari Therapeutics and Peak Bio Announce Portfolio Prioritization Plan for Combined Go-Forward Merger Entity
May 01, 2024 08:00 ET
|
Akari Therapeutics Plc
Prioritization of Peak’s ADC cancer therapeutic platform technology and Akari’s PAS-nomacopan for Geographic Atrophy, a disabling ophthalmic diseaseAkari Therapeutics announces leadership changes in...
Akari Therapeutics to Present PAS-Nomacopan Pre-Clinical Electroretinography (ERG) Data at ARVO 2024
April 15, 2024 08:00 ET
|
Akari Therapeutics Plc
BOSTON and LONDON, April 15, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today...
Akari Therapeutics Reports Full-Year 2023 Financial Results and Recent Highlights
April 01, 2024 06:30 ET
|
Akari Therapeutics Plc
BOSTON and LONDON, April 01, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory...
Akari Therapeutics and Peak Bio Announce Definitive Agreement to Merge as Equals Creating an Expanded Pipeline That Features a Novel Antibody Drug Conjugate (ADC) Toolkit
March 05, 2024 08:00 ET
|
Akari Therapeutics Plc
BOSTON and PLEASANTON, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and...
Akari Therapeutics Announces Existing Investors Support the Company Through a $2 Million Private Placement Financing
January 02, 2024 08:00 ET
|
Akari Therapeutics Plc
BOSTON and LONDON, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory...
Akari Therapeutics to Present at Biotech Showcase 2024
December 14, 2023 08:00 ET
|
Akari Therapeutics Plc
NEW YORK and BOSTON, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory...